All In Biotech

NDA 020908 · Novo Nordisk INC

Vagifem

Estradiol · Vaginal · Estrogen

Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Mar 26, 1999

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,701

351 Phase 3, 176 recruiting

FAERS reports

51,288

25,836 serious, 1,050 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA, and BREAST CANCER Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding [see Warnings and Precautions ( 5.3 )]. Cardiovascular Disorders and Probable Dementia The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment...

What it is approved for

From the label in effect Feb 10, 2025.

• Vagifem is an estrogen indicated for the treatment of atrophic vaginitis due to menopause ( 1.1 ). 1.1 Treatment of Atrophic Vaginitis due to Menopause

Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • VAGIFEM · ESTRADIOL 25MCG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, VAGINAL · Discontinued
  • VAGIFEM · ESTRADIOL 10MCG · TABLET, VAGINAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.

All 1,701 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,227
  • headache3,188
  • fatigue3,185
  • nausea3,175
  • off label use2,652
  • pain2,331
  • diarrhoea2,200
  • dizziness1,956
  • arthralgia1,954
  • breast cancer female1,721
  • dyspnoea1,714
  • pruritus1,707

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004562
2005617
2006459
20071,513
2008501
2009689
20101,089
2011947
20121,316
20131,057
20141,323
20152,222
20162,721
20172,436
20182,790
20193,242
20203,207
20213,051
20223,260
20233,760
20243,898
20255,447
20265,180

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vagifem (Estradiol)

2024 spending

$3.1M

Beneficiaries

2,322

7,733 claims

Per beneficiary

$1,323

$19.97 per unit

View as table
YearSpending
2020$4,945,697
2021$4,088,997
2022$3,662,059
2023$3,277,770
2024$3,072,848

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,476 on PubMed

Sponsor: Novo Nordisk

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.